MicroSectors Gold Miners -3X Inverse Leveraged ETNs

ProShares UltraShort Bloomberg Natrl Gas

ProShares UltraShort Silver

Bank Of Montreal

Direxion Daily Gold Miners Bear 3X ETF

VS TR 2x Long VIX Futures ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

Direxion Technology Bear 3X Shares

ARK Innovation ETF

MicroSectors Gold Miners 3X Leveraged ETN

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Silver

Direxion Daily Gold Miners Bull 3X ETF

United States Natural Gas

VanEck Vectors Junior Gold Miners ETF

Direxion Daily Semicondct Bull 3X ETF

iShares MSCI Japan

iShares Silver Trust

Direxion Daily Technology Bull 3X ETF

Kroger Company (The) Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Gray Television Inc. Common Stock

Hims & Hers Health Inc. Class A Common Stock

Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)

Carvana Co. Class A Common Stock

Carter's Inc. Common Stock

ICL Group Ltd. Ordinary Shares

Lennar Corporation Class A Common Stock

Olin Corporation Common Stock

AgEagle Aerial Systems Inc. Common Stock

KBR Inc. Common Stock

Oklo Inc.

Cleveland-Cliffs Inc. Common Stock

Arista Networks Inc. Common Stock

Grupo Aeroportuario Del Pacifico S.A. B. de C.V. Grupo Aeroportuario Del Pacifico S.A. de C.V. (each representing 10 Series B shares)

MINISO Group Holding Limited American Depositary Shares each representing four Ordinary Shares

Endeavour Silver Corporation Ordinary Shares (Canada)

Unity Software Inc. Common Stock

Dutch Bros Inc. Class A Common Stock

Click here to get full coverage on CLASS ACTION UPDATE for CTMX, CCL and FSCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

CLASS ACTION UPDATE for CTMX, CCL and FSCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders  ACCESS Newswire

CLASS ACTION UPDATE for CTMX, CCL and FSCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Click here to get full coverage on $CTMX stock is up 14% today. Here's what we see in our data. - Nasdaq

$CTMX stock is up 14% today. Here's what we see in our data.  Nasdaq

$CTMX stock is up 14% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching - simplywall.st

Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching  simplywall.st

Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching - simplywall.st

Click here to get full coverage on CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan

CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming  Stock Titan

CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan

Click here to get full coverage on CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For - Yahoo Finance

CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For  Yahoo Finance

CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For - Yahoo Finance

Click here to get full coverage on CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials  Value The Markets

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets

Click here to get full coverage on Insider Sale: Chief Financial Officer of $CTMX Sells 10,614 Shares - Nasdaq

Insider Sale: Chief Financial Officer of $CTMX Sells 10,614 Shares  Nasdaq

Insider Sale: Chief Financial Officer of $CTMX Sells 10,614 Shares - Nasdaq

Click here to get full coverage on CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story  simplywall.st

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

Click here to get full coverage on CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know  Yahoo Finance

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock | CTMX Stock News - Stock Titan

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock | CTMX Stock News  Stock Titan

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock | CTMX Stock News - Stock Titan

Click here to get full coverage on CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates  Yahoo Finance

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on $CTMX stock is up 8% today. Here's what we see in our data. - Nasdaq

$CTMX stock is up 8% today. Here's what we see in our data.  Nasdaq

$CTMX stock is up 8% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on CytomX Unveils Breakthrough Cancer Treatment Data with Moderna at AACR | CTMX Stock News - Stock Titan

CytomX Unveils Breakthrough Cancer Treatment Data with Moderna at AACR | CTMX Stock News  Stock Titan

CytomX Unveils Breakthrough Cancer Treatment Data with Moderna at AACR | CTMX Stock News - Stock Titan

Click here to get full coverage on New Analyst Forecast: $CTMX Given 'Overweight' Rating - Nasdaq

New Analyst Forecast: $CTMX Given 'Overweight' Rating  Nasdaq

New Analyst Forecast: $CTMX Given 'Overweight' Rating - Nasdaq

Click here to get full coverage on CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...  Yahoo Finance

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Click here to get full coverage on Can CytomX's 36% Revenue Surge Fund Its Next-Gen Cancer Drug Breakthrough? - Stock Titan

Can CytomX's 36% Revenue Surge Fund Its Next-Gen Cancer Drug Breakthrough?  Stock Titan

Can CytomX's 36% Revenue Surge Fund Its Next-Gen Cancer Drug Breakthrough? - Stock Titan

Click here to get full coverage on HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq

HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX)  Nasdaq

HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq

Click here to get full coverage on CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance

CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates  Yahoo Finance

CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors - Stock Titan

Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors  Stock Titan

Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors - Stock Titan

Click here to get full coverage on Insider Sale: CEO of $CTMX Sells 37,656 Shares - Nasdaq

Insider Sale: CEO of $CTMX Sells 37,656 Shares  Nasdaq

Insider Sale: CEO of $CTMX Sells 37,656 Shares - Nasdaq

Click here to get full coverage on Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st

Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership  simplywall.st

Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st

Click here to get full coverage on Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan

Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study  Stock Titan

Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan

Click here to get full coverage on All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy - Yahoo Finance

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy  Yahoo Finance

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy - Yahoo Finance

Click here to get full coverage on CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha

CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ)  Seeking Alpha

CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha

Click here to get full coverage on CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Stock Titan

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update  Stock Titan

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Stock Titan

Click here to get full coverage on CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus

CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News  GuruFocus

CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus

Click here to get full coverage on CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering (CTMX:NASDAQ) - Seeking Alpha

CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering (CTMX:NASDAQ)  Seeking Alpha

CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering (CTMX:NASDAQ) - Seeking Alpha

Click here to get full coverage on CytomX Slashes 40% of Workforce, Prioritizes Cancer Drug Pipeline in Strategic Overhaul - Stock Titan

CytomX Slashes 40% of Workforce, Prioritizes Cancer Drug Pipeline in Strategic Overhaul  Stock Titan

CytomX Slashes 40% of Workforce, Prioritizes Cancer Drug Pipeline in Strategic Overhaul - Stock Titan

Click here to get full coverage on CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical - GuruFocus

CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical  GuruFocus

CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical - GuruFocus

Click here to get full coverage on Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround  Yahoo Finance

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance

Click here to get full coverage on CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha

CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish?  Seeking Alpha

CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha

Click here to get full coverage on CytomX Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:CTMX) - Seeking Alpha

CytomX Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:CTMX)  Seeking Alpha

CytomX Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:CTMX) - Seeking Alpha

Click here to get full coverage on CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus

CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News  GuruFocus

CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus

Click here to get full coverage on CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) - Yahoo Finance

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)  Yahoo Finance

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) - Yahoo Finance

Click here to get full coverage on CytomX Regains Nasdaq Compliance, Stabilizes Market Position - TipRanks

CytomX Regains Nasdaq Compliance, Stabilizes Market Position  TipRanks

CytomX Regains Nasdaq Compliance, Stabilizes Market Position - TipRanks

Click here to get full coverage on CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next  simplywall.st

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

Click here to get full coverage on CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus

CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News  GuruFocus

CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus

Click here to get full coverage on Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock - Latham & Watkins LLP

Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock  Latham & Watkins LLP

Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock - Latham & Watkins LLP

Click here to get full coverage on After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals

After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff  The Business Journals

After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals

Click here to get full coverage on Stocks Under $1 to Watch: TAOP, WLGS, HIT, CTMX, JYD – Major Updates, Earnings & Offerings, More Inside…. - FinancialContent

Stocks Under $1 to Watch: TAOP, WLGS, HIT, CTMX, JYD – Major Updates, Earnings & Offerings, More Inside….  FinancialContent

Stocks Under $1 to Watch: TAOP, WLGS, HIT, CTMX, JYD – Major Updates, Earnings & Offerings, More Inside…. - FinancialContent

Click here to get full coverage on CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks

CytomX Therapeutics Secures $93.4 Million Through Stock Sale  TipRanks

CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks

Click here to get full coverage on CytomX stock falls on portfolio shakeup (CTMX:NASDAQ) - Seeking Alpha

CytomX stock falls on portfolio shakeup (CTMX:NASDAQ)  Seeking Alpha

CytomX stock falls on portfolio shakeup (CTMX:NASDAQ) - Seeking Alpha

Click here to get full coverage on CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations  Yahoo Finance

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Click here to get full coverage on CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Yahoo Finance

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock  Yahoo Finance

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Yahoo Finance

Click here to get full coverage on CytomX Therapeutics Reports Positive Interim Phase 1 Data - TipRanks

CytomX Therapeutics Reports Positive Interim Phase 1 Data  TipRanks

CytomX Therapeutics Reports Positive Interim Phase 1 Data - TipRanks

Click here to get full coverage on CytomX faces Nasdaq delisting over share price woes - Investing.com

CytomX faces Nasdaq delisting over share price woes  Investing.com

CytomX faces Nasdaq delisting over share price woes - Investing.com

Click here to get full coverage on CytomX Gears Up to Report Q1 Earnings: Here's What to Expect - Zacks Investment Research

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect  Zacks Investment Research

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect - Zacks Investment Research

Click here to get full coverage on Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report  Benzinga

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga

Click here to get full coverage on CytomX stock hits 52-week low at $0.74 amid market challenges - Investing.com

CytomX stock hits 52-week low at $0.74 amid market challenges  Investing.com

CytomX stock hits 52-week low at $0.74 amid market challenges - Investing.com

Click here to get full coverage on H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com

H.C. Wainwright raises CytomX stock to buy, target to $5.00  Investing.com

H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com

Click here to get full coverage on CytomX Therapeutics, Inc. SEC 10-Q Report - TradingView

CytomX Therapeutics, Inc. SEC 10-Q Report  TradingView

CytomX Therapeutics, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 | CTMX Stock News - GuruFocus

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 | CTMX Stock News  GuruFocus

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 | CTMX Stock News - GuruFocus

Click here to get full coverage on CytomX stock plunges to 52-week low, touches $0.6 - Investing.com

CytomX stock plunges to 52-week low, touches $0.6  Investing.com

CytomX stock plunges to 52-week low, touches $0.6 - Investing.com

Click here to get full coverage on CytomX shares priced at $1.30 in $100 million offering - Investing.com

CytomX shares priced at $1.30 in $100 million offering  Investing.com

CytomX Therapeutics Inc (CTMX)

Price Chart

Key Statistics

Technicals

About CTMX

Latest News

CLASS ACTION UPDATE for CTMX, CCL and FSCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

$CTMX stock is up 14% today. Here's what we see in our data. - Nasdaq

Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching - simplywall.st

Advanced Charts

Top Gainers

Top Losers